Galenica

Pharmaceuticals

GALE.SW

CHF 76 (1.3)%

Share price

$ 4.3 bn

Market Cap

$ 5.1 bn

Enterprise Value

Carbon footprint

GHG emissions per $ 1 mln investment

0.04x the weighted average for S&P 500

FY2021

Primary Climate Goal

This company has not set a company-wide target for an absolute reduction in GHG emissions yet

GHG emissions and Carbon intensity

Galenica reported Total CO2e Emissions - Location-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 7.7 Kt (+1.4/+22% y-o-y). Carbon intensity also grew to 1.8 t (+0.1/+5.9% y-o-y).

Galenica's Scope 3 emissions grew to 4.4 Kt (+0.14/+3.2% y-o-y). The growth rate declined vs. the previous periods (CAGR +7.6% since 4Q'17).

The company has not set a company-wide target for an absolute reduction in GHG emissions yet.

Date	Total CO2e emissions (location-based Scope 1 & 2) (Kt)	Scope 1	Scope 2	Scope 3	Revenue (USDm)	Carbon intensity (tons of CO2e) / (USDm)
2021Q4	7.7	5.7	2	4.4	4,208	1.8
2020Q4	6.3	4.3	2.1	4.2	3,788	1.7
2019Q4	5.2	3	2.1	3.9	3,353	1.5
2018Q4	5.4	3.1	2.2	3.6	3,241	1.7
2017Q4	4.8	3	1.8	3	3,192	1.5

Galenica

Carbon footprint

Primary Climate Goal

This company has not set a company-wide target for an absolute reduction in GHG emissions yet

GHG emissions and Carbon intensity

Galenica's carbon footprint

Company environmental metrics